Project Grant R43HL184714
Award Date 8/10/26
Completion Date 7/31/27
Dollars Obligated $379K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30309, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded $404,424 to Texas A&M Engineering Experiment Station on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an extracellular matrix–based lymphatic patch with valved pre-collectors that restores lymphatic function and supports unidirectional lymph flow. The project addresses a gap in current regenerative approaches that promote lymphangiogenesis but fail to engineer larger...
- The National Heart, Lung, and Blood Institute awarded Matregenix Inc. $314,211 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biodegradable, drug-eluting nanofiber scaffolds for lymphatic regeneration and lymphedema treatment. Matregenix will fabricate flexible, tubular scaffolds composed of amino acid-based poly(ester urea) designed to deliver sustained, localized 9-cis retinoic acid to promote lymphangiogenesis. Phase I objectives include...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $950,550 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop translational magnetic resonance imaging technologies that visualize sodium accumulation and lymphatic physiology in lymphedema and lipedema. The research program, titled "Visualizing Sodium in Lymphatic Disease: A Translational Path," pursues three integrated translational goals: understanding disease...
- The National Heart, Lung, and Blood Institute awarded Fastline LLC $306,383 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test a second-generation one-handed central venous line (CVL) placement device. Fastline is engineering a simplified CVL insertion device that enables operators to perform all steps of central vein access—needle puncture, aspiration/injection, manometry testing, and guidewire placement—with a single hand while...
- The National Institute of Biomedical Imaging and Bioengineering awarded Tissuelock LLC $314,362 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an antioxidative fiber mesh adhesive for preventing seroma and hematoma complications following abdominoplasty and large soft tissue surgeries. Seromas and hematomas occur in up to 20–30% of these procedures, leading to infection, delayed healing, repeat...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Aventusoft LLC $500,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercialization of HEMOLINK, a skin-adhered disposable patch for non-invasive hemodynamic monitoring. HEMOLINK is a first-in-class wearable medical device featuring a synchronous quad-sensor array designed to estimate left ventricular end-diastolic pressure (LVEDP) for remote cardiac monitoring. The patch incorporates...
- The National Heart Lung and Blood Institute awarded Venostent, Inc. $1,016,974 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support pilot-scale synthesis and commercialization of SelfWrap, a bioabsorbable perivascular wrap designed to improve outcomes in arteriovenous fistula creation and other vascular surgeries. SelfWrap addresses the high failure rate of arteriovenous fistulas (AVFs) created for hemodialysis access. Veins used in AVF surgery are...